logo
Plus   Neg
Share
Email

ViiV Healthcare Seeks FDA Approval For Two-drug To Treat HIV-1 Infection

ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK.L,GSK) and Pfizer Inc. (PFE), has submitted a New Drug Application to the US Food and Drug Administration seeking approval for an investigational, monthly, injectable, two-drug regimen of Rilpivirine and Cabotegravir for the treatment of HIV.

In pivotal phase III studies, dubbed ATLAS and FLAIR, the combination of Janssen's Rilpivirine and ViiV's Cabotegravir injected monthly, was as effective as a standard of care, daily, oral, three-drug regimen in maintaining viral suppression throughout the 48-week study period.

ViiV Healthcare and Janssen plan to submit regulatory applications for the two-drug regimen of cabotegravir and rilpivirine to the European Medicines Agency, Health Canada and other global agencies in the coming months.

As part of the regulatory submission package to the FDA, a second NDA was submitted for an oral tablet formulation of Cabotegravir that would be taken once-daily as an oral lead-in with the already-approved oral tablet formulation of Rilpivirine (marketed by Janssen as EDURANT).

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. is taking necessary precautions including Covid-19 testing for those employees returning to work at its headquarters in Silicon Valley, Bloomberg reported citing people familiar with the process. The company, which opened its main Apple Park office in May bringing back some hardware and software engineers, plans the gradual reopening of the building keeping the coronavirus safeguards. A U.S. appeals court has blocked the sales of Bayer AG's dicamba-based Xtendimax in the United States. The three-judge panel in the U.S. Court of Appeals for the Ninth Circuit ruled that the US Environmental Protection Agency (EPA) overstated the protections and substantially understated or ignored the risks related to the use of dicamba-based herbicides. Tesla Chief Executive Officer Elon Musk has called for a breakup of Amazon after the online retail giant refused to publish an upcoming book about COVID-19. Writer Alex Berenson said on Twitter that Amazon refused to publish his booklet about the coronavirus as it did not comply with the company's guidelines. Berenson is a former New York Times reporter.
Follow RTT